TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05643742: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Sponsor: CRISPR Therapeutics AG · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$11,820,270

Rescue Site Savings

+$7,814,730

Unlock Full NCT05643742 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05643742 Rescue Dossier →